342 related articles for article (PubMed ID: 16371868)
1. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.
Chaix ML; Rouet F; Kouakoussui KA; Laguide R; Fassinou P; Montcho C; Blanche S; Rouzioux C; Msellati P
Pediatr Infect Dis J; 2005 Dec; 24(12):1072-6. PubMed ID: 16371868
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
[TBL] [Abstract][Full Text] [Related]
3. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire.
Adjé-Touré C; Hanson DL; Talla-Nzussouo N; Borget MY; Kouadio LY; Tossou O; Fassinou P; Bissagnene E; Kadio A; Nolan ML; Nkengasong JN
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):911-7. PubMed ID: 18593341
[TBL] [Abstract][Full Text] [Related]
4. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
5. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
Chiappini E; Galli L; Zazzi M; de Martino M
J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.
Adjé-Touré C; Celestin B; Hanson D; Roels TH; Hertogs K; Larder B; Diomande F; Peeters M; Eholié S; Lackritz E; Chorba T; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S23-9. PubMed ID: 14565606
[TBL] [Abstract][Full Text] [Related]
7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
8. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
Adjé C; Cheingsong R; Roels TH; Maurice C; Djomand G; Verbiest W; Hertogs K; Larder B; Monga B; Peeters M; Eholie S; Bissagene E; Coulibaly M; Respess R; Wiktor SZ; Chorba T; Nkengasong JN;
J Acquir Immune Defic Syndr; 2001 Apr; 26(5):501-6. PubMed ID: 11391173
[TBL] [Abstract][Full Text] [Related]
10. Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.
Walenda C; Kouakoussui A; Rouet F; Wemin L; Anaky MF; Msellati P
J Trop Pediatr; 2009 Jun; 55(3):170-6. PubMed ID: 19066169
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
[TBL] [Abstract][Full Text] [Related]
13. Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.
Tchounga BK; Charpentier C; Coffie PA; Dabis F; Descamps D; Eholie SP; Ekouevi DK
PLoS One; 2020; 15(8):e0236642. PubMed ID: 32756581
[TBL] [Abstract][Full Text] [Related]
14. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
16. Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Côte d'Ivoire: ANRS 1257 study.
Toni TD; Recordon-Pinson P; Minga A; Ekouevi D; Bonard D; Bequet L; Huet C; Chenal H; Rouet F; Dabis F; Lafon ME; Salamon R; Masquelier B; Fleury HJ
AIDS Res Hum Retroviruses; 2003 Aug; 19(8):713-7. PubMed ID: 14506786
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006.
Toni Td; Masquelier B; Minga A; Anglaret X; Danel C; Coulibaly A; Chenal H; Dabis F; Salamon R; Fleury HJ;
AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1155-60. PubMed ID: 17919113
[TBL] [Abstract][Full Text] [Related]
18. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire.
Fassinou P; Elenga N; Rouet F; Laguide R; Kouakoussui KA; Timite M; Blanche S; Msellati P
AIDS; 2004 Sep; 18(14):1905-13. PubMed ID: 15353976
[TBL] [Abstract][Full Text] [Related]
19. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
20. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
Seyler C; Adjé-Touré C; Messou E; Dakoury-Dogbo N; Rouet F; Gabillard D; Nolan M; Toure S; Anglaret X
AIDS; 2007 May; 21(9):1157-64. PubMed ID: 17502726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
